Related Experiment Videos

Possible olanzapine-induced hepatotoxicity in a young Chinese patient

S Y Lui1, Steve Tso, M Lam

  • 1Castle Peak Hospital, Tuen Mun, Hong Kong. simonsylui@yahoo.com.hk

Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|October 6, 2009
PubMed

Insights

A young man with schizophrenia experienced liver damage, jaundice, and an enlarged spleen after taking olanzapine. These symptoms resolved upon medication discontinuation, highlighting olanzapine hepatotoxicity risks.

Area of Science:

  • Hepatology
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia is a severe mental disorder often treated with antipsychotic medications.
  • Olanzapine is a commonly prescribed atypical antipsychotic for schizophrenia.
  • Drug-induced liver injury is a potential adverse effect of various medications.

Observation:

  • A 17-year-old male patient with a first episode of schizophrenia was treated with olanzapine.
  • The patient developed symptoms indicative of hepatitis, cholestasis, and splenomegaly.
  • These adverse effects emerged during olanzapine therapy.

Findings:

  • The patient's liver function tests indicated hepatitis and cholestasis.
  • Splenomegaly was observed in conjunction with the liver abnormalities.
  • Cessation of olanzapine led to the complete reversal of hepatitis, cholestasis, and splenomegaly.

Implications:

  • Olanzapine can cause significant hepatotoxicity, including cholestasis and splenomegaly.
  • Early detection through patient education and clinical vigilance is crucial for managing olanzapine-induced liver injury.
  • Healthcare providers should monitor patients on olanzapine for signs of liver dysfunction.

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...